Evaluating off-target drug effects seen in RCTs using proteomics and mendelian randomisation

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Ms Jennifer Brody

University of Washington, Seattle (United States of America)

7 More presentations in this session

Presentation thumbnail

Potential use of pharmacogenetics in cardiology: genome-wide association studies of amiodarone-induced thyroid disorders

Mr S. Rand (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

Pharmacogenomics of CRP response to statins: a GIST consortium study

Doctor E. Magavern (London, GB)

Abstract Slides Video

Presentation thumbnail

Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis

Doctor M. Galli (Rome, IT)

Abstract Slides Video

Presentation thumbnail

Real-world implementation of a genotype-guided p2y12-inhibitor de-escalation strategy in acute coronary syndrome patients

Doctor J. Azzahhafi (Nieuwegein, NL)

Abstract Slides Video

Presentation thumbnail

Limited visibility and uptake of the clopidogrel pharmacogenomic guidelines among cardiologists

Doctor L. Venetucci (Manchester, GB)

Abstract Slides Video

Access the full session

Session thumbnail

Pharmacogenomics, cardio-omics, and cardiovascular drugs

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

HFWM: Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation

Congress Presentation

From proteomics to precision: protein signatures as surrogate markers in phase II heart failure trials. A subanalysis from MYSTERY-HF

Congress Presentation

Pharmacogenomics of CRP response to statins: a GIST consortium study

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources